Anti-inflammatory acne-eliminating face cream and preparation method thereof
By mixing ingredients such as horse oil with natural extracts such as water shield polysaccharides to form a stable microemulsion system and adding gardenia essential oil, the problem of difficulty in developing anti-inflammatory and acne-relieving creams in the existing technology is solved, and anti-inflammatory, It has multiple effects of acne elimination, whitening and moisturizing, and ensures the safety and stability of the product.
Patent Information
- Application Number
- CN202411132604.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-22
AI Technical Summary
It is difficult to develop natural plant-based creams with anti-inflammatory and acne-relieving effects in the prior art, especially a microemulsion system with good stability and effective penetration of the skin.
The A phase and B phase are mixed with components. Phase A includes horse oil, cetaceous alcohol, PEG-100 stearate and natural 16 alcohols. Phase B includes water shield polysaccharide extract, licorice extract, calendula Extract solution, chamomile extract, knotweed extract, poria cocos extract, peony root crust solution, ascorbic acid solution, arbutin solution and sodium hyaluronate, the extract solution is prepared by ultrasonic extraction and water bath extraction to form a stable micro-micron and add gardenia essential oil.
It achieves multiple effects of anti-inflammatory, acne elimination, whitening and moisturizing, inhibits skin inflammation, reduces acne symptoms, and does not contain harmful chemicals, which is safe and reliable.
Smart Images

Figure CN118986784A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of cosmetic products, and in particular to an anti-inflammatory and anti-acne facial cream and a preparation method thereof. Background Art
[0002] Acne, also known as pimples, is a chronic skin disease characterized by skin rashes. It is more common among adolescents. Studies have found that acne is a complex disease affected by multiple factors. The main mechanisms of its occurrence and development include excessive androgen secretion, abnormal bacterial proliferation, increased sebum production, abnormal keratinization of sebaceous gland ducts, inflammatory response, and obstruction of sebaceous ducts. In addition, the occurrence of acne is also affected by other factors, such as smoking, diet, obesity, ultraviolet radiation, and stress. According to the severity of acne, it can be divided into four main levels from level one to level four. Level one is characterized by non-inflammatory acne and a small number of papules, level two is composed of acne, papules, and a few pustules, and level three acne is characterized by larger papules, pustules, and a small number of cysts, which may involve the face, neck, and upper trunk. Level four is the most serious stage of acne, characterized by nodules, cysts, and even scar formation. Most patients with acne with a severe course of disease will develop irreversible skin inflammatory changes and require long-term and complex treatment. The presence of cosmetic defects has a negative impact on the patient's psychological emotions, which can reduce the patient's self-esteem and cause psychological depression.
[0003] Many cosmetics on the market contain chemical ingredients. Long-term use of cosmetics containing such substances can cause thinning of the skin, dilation of capillaries, skin allergies, and promote the occurrence of acne. How to prepare green, safe, and efficient skin care products has always been a hot topic and difficult problem in the cosmetics industry. Summary of the invention
[0004] Traditional Chinese medicine cosmetics are made by adding effective ingredients of traditional Chinese medicine using modern science and technology. They have the functions of cleansing the body, nourishing and moisturizing, improving appearance, beautifying the appearance, etc. They have obvious effects, mild nature, low irritation, and are safer and more reliable than cosmetics synthesized from chemical raw materials. As the most commonly used daily cosmetics, facial creams are generally rich in texture and have a more significant moisturizing effect than lotions. They can form a barrier on the surface of the skin, preventing water evaporation while also reducing damage to the skin caused by the outside world. Facial creams are generally tiny liquid particles of oil-in-water or water-in-oil, which can better allow effective substances to penetrate the skin, deeply activate cells, and replenish collagen. Therefore, it is a difficult problem in the prior art to apply natural plant effective ingredients to facial creams to form a microemulsion system with good stability and synergistic effects of active ingredients, especially it is difficult to obtain facial creams with specific effects such as anti-inflammatory and anti-acne.
[0005] The purpose of the present invention is to overcome the above technical deficiencies, provide an anti-inflammatory and anti-acne cream and a preparation method thereof, and solve the technical problem of how to use natural plants to obtain a cream with anti-inflammatory and anti-acne effects in the prior art.
[0006] In order to achieve the above technical purpose, the technical solution of the present invention provides an anti-inflammatory and anti-acne facial cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 30-40% horse oil, 2-5% cetearyl alcohol, 1.5-3% PEG-100 stearate, and 3-5% natural 16 alcohol; the components of phase B include: 10-30% water shield polysaccharide extract, 4-8% licorice extract, 4-8% calendula extract, 4-8% chamomile extract, 4-8% knotweed extract, 4-8% poria extract, 10-15% peony root bark solution, 1-2% ascorbic acid solution, 2-3% arbutin solution, 0.2-0.3% xanthan gum, and 4%-5% sodium hyaluronate; the amount of the gardenia essential oil is 0.1-0.3%.
[0007] In any embodiment, the components of phase A include: 30% horse oil, 2% cetearyl alcohol, 1.5% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 20% water shield polysaccharide extract, 6% licorice extract, 6% calendula extract, 6% chamomile extract, 6% knotweed extract, 6% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil used is 0.2%.
[0008] In any embodiment, the crude drug concentration of the Brasenia schrenkiana polysaccharide extract, the Licorice extract or the Poria cocos extract is 0.1-0.15 g / mL, and the Brasenia schrenkiana polysaccharide extract, the Licorice extract or the Poria cocos extract is prepared by the following steps:
[0009] The water shield powder, licorice powder or poria powder are respectively mixed with water at a material-liquid mass ratio of 1:40-50, ultrasonically extracted at 60-80°C, and then filtered and centrifuged to obtain the product.
[0010] In any embodiment, the crude drug concentration of the calendula extract or the chamomile extract is 0.1-0.15 g / mL, and the calendula extract or the chamomile extract is prepared by the following steps:
[0011] Calendula powder or chamomile powder is mixed with ethanol solution at a material-liquid mass ratio of 1:20-25, reacted in a water bath at 55-60° C. for 2-2.5 hours, then activated carbon powder is added for decolorization, and then filtered to obtain the calendula extract or the chamomile extract.
[0012] In any embodiment, the crude drug concentration of the Polygonum cuspidatum extract is 0.1-0.15 g / mL, and the Polygonum cuspidatum extract is prepared by the following steps:
[0013] The knotweed powder and water are mixed, and the mixture is soaked at 35-40°C to obtain a knotweed liquid. Cellulase solution is added to the knotweed liquid, and the mixture is extracted at 45-50°C and filtered to obtain a filtrate. The filtrate is inactivated to obtain a supernatant, the supernatant is centrifuged and activated carbon is added, and then filtered and concentrated to obtain the knotweed extract.
[0014] In any embodiment, the mass concentration of the peony root bark solution, the ascorbic acid solution or the arbutin solution is 100-110 mg / mL.
[0015] In addition, the present invention also provides a method for preparing the above-mentioned anti-inflammatory and anti-acne cream, comprising the following steps:
[0016] Mix the components in phase A, then heat phase A to 75-80°C;
[0017] Mix the components of phase B and heat to dissolve, and raise the temperature to 75-80°C;
[0018] Add phase B to phase A, start homogenization, cool to 40-50° C. after homogenization, add gardenia essential oil and continue homogenization to obtain the anti-inflammatory and anti-acne cream.
[0019] In any embodiment, phase B is added to phase A, and the homogenization speed is 450-500 rpm, and the homogenization time is 5-8 min.
[0020] In any embodiment, the gardenia essential oil is added and the homogenization speed is continued at 250-300 rpm, and the homogenization time is 2-3 min.
[0021] In any embodiment, after adding the gardenia essential oil and continuing to homogenize, the process further includes stirring for 3-5 minutes and then degassing.
[0022] Compared with the prior art, the beneficial effects of the present invention include: the facial cream proposed by the present invention, with the cooperation of various components, especially by adding natural plant ingredients such as 10-30% of Brasenia schrenkiana polysaccharide extract, 4-8% of licorice extract, 4-8% of calendula extract, 4-8% of chamomile extract, 4-8% of Polygonum cuspidatum extract, 4-8% of Poria cocos extract, and 10-15% of peony root bark solution, can absorb ultraviolet rays to block the skin from being irradiated by ultraviolet rays, reduce the oxidation of the skin stratum corneum and the precipitation of melanin, improve the antioxidant and whitening effects, and at the same time inhibit the growth of Staphylococcus aureus and Escherichia coli on the skin surface, reduce acne inflammation, and eliminate redness and swelling. In addition, the microemulsion system is stable, the cosmetics do not contain harmful chemicals, and the facial cream has the effects of eliminating acne, whitening and moisturizing. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The relative expression levels of IL-1 and RELA (NF-κB p65) mRNA in the mouse skin of the Control group, Model group, XYBC group (Xiangyi Bencao group), 25% concentration cream group, 50% concentration cream group of Example 2, 75% concentration cream group of Example 2, and 100% concentration cream group of Example 2 of the present invention (p<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
[0024] Figure 2 The expression levels of p-NF-κB p65 and NF-κB p65 protein in the back skin lesions of mice were affected by the facial cream of Example 2 of the present invention. DETAILED DESCRIPTION
[0025] The present specific embodiment provides an anti-inflammatory and anti-acne facial cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 30-40% horse oil, 2-5% cetearyl alcohol, 1.5-3% PEG-100 stearate, and 3-5% natural 16 alcohol; the components of phase B include: 10-30% water shield polysaccharide extract, 4-8% licorice extract, 4-8% calendula extract, 4-8% chamomile extract, 4-8% knotweed extract, 4-8% poria extract, 10-15% peony root bark solution, 1-2% ascorbic acid solution, 2-3% arbutin solution, 0.2-0.3% xanthan gum, and 4%-5% sodium hyaluronate; the amount of the gardenia essential oil is 0.1-0.3%.
[0026] In certain embodiments, the components of phase A include: 30% horse oil, 2% cetearyl alcohol, 1.5% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 20% water shield polysaccharide extract, 6% licorice extract, 6% calendula extract, 6% chamomile extract, 6% knotweed extract, 6% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil used is 0.2%.
[0027] In certain embodiments, the herbal drug concentration of the Brasenia schrenkiana polysaccharide extract, the Licorice extract or the Poria cocos extract is 0.1-0.15 g / mL, and the Brasenia schrenkiana polysaccharide extract, the Licorice extract or the Poria cocos extract is prepared by the following steps:
[0028] The water shield powder, licorice powder or poria powder are respectively mixed with water at a material-liquid mass ratio of 1:40-50, ultrasonically extracted at 60-80°C, and then filtered and centrifuged to obtain the product.
[0029] In certain embodiments, the herbal drug concentration of the calendula extract or the chamomile extract is 0.1-0.15 g / mL, and the calendula extract or the chamomile extract is prepared by the following steps:
[0030] Calendula powder or chamomile powder is mixed with ethanol solution at a material-liquid mass ratio of 1:20-25, reacted in a water bath at 55-60° C. for 2-2.5 hours, then activated carbon powder is added for decolorization, and then filtered to obtain the calendula extract or the chamomile extract.
[0031] In certain embodiments, the crude drug concentration of the Polygonum cuspidatum extract is 0.1-0.15 g / mL, and the Polygonum cuspidatum extract is prepared by the following steps:
[0032] The knotweed powder and water are mixed, and the mixture is soaked at 35-40°C to obtain a knotweed liquid. Cellulase solution is added to the knotweed liquid, and the mixture is extracted at 45-50°C and filtered. The filtrate is inactivated to obtain a supernatant, the supernatant is centrifuged and activated carbon is added, and then filtered and concentrated to obtain the knotweed extract.
[0033] In the present invention, the crude drug concentration is, for example, 0.1 g / ml, which means the amount of raw material (10 g) / the volume of the drug solution (100 ml).
[0034] In addition, the present invention also provides a method for preparing the above-mentioned anti-inflammatory and anti-acne cream, comprising the following steps:
[0035] Mix the components in phase A, then heat phase A to 75-80°C;
[0036] Mix the components of phase B and heat to dissolve, and raise the temperature to 75-80°C;
[0037] Add phase B to phase A and start homogenization at a speed of 450-500 rpm for 5-8 min. After homogenization, cool to 40-50° C., add gardenia essential oil and continue homogenizing to obtain the anti-inflammatory and anti-acne cream. Add gardenia essential oil and continue homogenizing at a speed of 250-300 rpm for 2-3 min. Stir for 3-5 min and defoam.
[0038] Each extract in the following examples was prepared by the following steps:
[0039] 1. Polygonum cuspidatum extract: Weigh 10g of Polygonum cuspidatum powder, add 200mL of distilled water, soak at 35°C for 30min, add activated cellulose solution to the Polygonum cuspidatum liquid, slowly add and stir continuously, extract at 45°C for 2.5h, stir gently during the extraction process, filter, save the filtrate, collect the filter residue, add 200mL of water and activated enzyme solution to the filter residue, extract at 45°C for 2.5h, filter, combine the filtrate, remove the filter residue, heat the filtrate at 100°C for inactivation for 10min, take the supernatant, centrifuge the supernatant at 5000r / min for 15min, pretreat the activated carbon, add 1.5% of activated carbon powder to the extract, decolorize at a constant temperature for 90min under 50°C water bath conditions, filter while hot, and concentrate under reduced pressure to 100mL to obtain an extract with a decolorization rate of 72.5% and a mass concentration of 100mg / mL (crude drug concentration of 0.1g / mL).
[0040] 2. Poria extract: Weigh 10g of Poria powder, add distilled water with a solid-liquid ratio of 1:35, extract by ultrasonic at 60℃ for 50min, extraction power of 400W, filter the supernatant, centrifuge at 5000R / min for 15min at room temperature, and concentrate to 100mL of extract with a mass concentration of 100mg / mL (crude drug concentration is 0.1g / mL).
[0041] 3. Licorice extract: Weigh 10g of licorice powder, add distilled water with a solid-liquid ratio of 1:40, ultrasonically extract at 80℃ for 20min, the extraction power is 630W, filter the supernatant, centrifuge at 5000R / min for 15min at room temperature, and concentrate at 50℃ to 100mL of extract, with a mass concentration of 100mg / mL (crude drug concentration is 0.1g / mL).
[0042] 4. Calendula extract: weigh 10g of calendula powder, add 75% ethanol solution with a solid-liquid ratio of 1:20, incubate in a 55℃ water bath for 2h, filter and take the supernatant, repeat twice, and combine the filtrates.
[0043] After centrifugation, the mixture was concentrated under reduced pressure until the ethanol was removed to obtain a filtrate. The activated carbon was pretreated, and 1.5% activated carbon powder was added to the extract. The mixture was decolorized at a constant temperature of 50°C in a water bath for 90 minutes. The extract was filtered while hot to obtain a calendula extract with a decolorization rate of 55.4% and a mass concentration of 100 mg / mL (the crude drug concentration was 0.1 g / mL).
[0044] 5. Chamomile extract: Weigh 10g of chamomile powder, add 75% ethanol solution in a ratio of 1:20, place in a water bath at 55℃ for 2h, filter and take the supernatant, repeat twice, combine the filtrates, centrifuge, and then concentrate under reduced pressure until the ethanol is removed to obtain the filtrate. Pretreat the activated carbon, add 1.5% activated carbon powder to the extract, decolorize at a constant temperature in a water bath at 50℃ for 90min, filter the chamomile extract while it is hot, the decolorization rate is 59%, and its mass concentration is 100mg / mL (the crude drug concentration is 0.1g / mL).
[0045] 6. Water shield polysaccharide extract: Rinse fresh water shield with pure water, decolorize it with anhydrous ethanol several times, dry and crush it, weigh 10g of water shield powder, add distilled water with a solid-liquid ratio of 1:40, ultrasonically extract at 60℃ for 50min, the extraction power is 450W, filter the supernatant, centrifuge at 5000R / min at room temperature for 15min, concentrate the extract to 100mL with a mass concentration of 100mg / mL (the crude drug concentration is 0.1g / mL).
[0046] In the following examples, the peony root bark solution was purchased from Tuge Raw Material Wholesale Store, and the ascorbic acid solution or the arbutin solution was purchased from Shanghai MacLean Biochemical Technology Co., Ltd., with a mass concentration of 100-110 mg / mL. The specific information is shown in the following table:
[0047]
[0048]
[0049] The present embodiment provides an anti-inflammatory and anti-acne facial cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 35% horse oil, 3% cetearyl alcohol, 2% PEG-100 stearate, and 4% natural 16 alcohol; the components of phase B include: 25% water shield polysaccharide extract, 5% licorice extract, 5% calendula extract, 5% chamomile extract, 5% knotweed extract, 5% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil used is 0.2%.
[0050] The anti-inflammatory and anti-acne facial cream of the present embodiment is prepared by the following steps:
[0051] Mix the components in phase A, then heat phase A to 75°C;
[0052] Mix the components of phase B and heat to dissolve, and raise the temperature to 75°C;
[0053] Add phase B to phase A, start homogenization, set the homogenization speed to 500 rpm, and homogenize for 5 minutes. After homogenization, cool to 45°C, add gardenia essential oil and continue homogenizing to obtain the anti-inflammatory and anti-acne cream. Add gardenia essential oil and continue homogenizing at a speed of 300 rpm for 2 minutes, then stir for 3 minutes and defoam.
[0054] Example 2
[0055] The present embodiment provides an anti-inflammatory and anti-acne facial cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 30% horse oil, 2% cetearyl alcohol, 1.5% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 20% water shield polysaccharide extract, 6% licorice extract, 6% calendula extract, 6% chamomile extract, 6% knotweed extract, 6% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil used is 0.1%.
[0056] The anti-inflammatory and anti-acne facial cream of the present embodiment is prepared by the following steps:
[0057] Mix the components in phase A, then heat phase A to 75°C;
[0058] Mix the components of phase B and heat to dissolve, and raise the temperature to 75°C;
[0059] Add phase B to phase A, start homogenization, the homogenization speed is 500 rpm, the homogenization time is 6 minutes, cool to 40°C after homogenization, add gardenia essential oil and continue homogenization to obtain the anti-inflammatory and anti-acne cream, add gardenia essential oil and continue homogenization at a speed of 300 rpm, the homogenization time is 2 minutes, and then stir for 4 minutes and defoam.
[0060] Example 3
[0061] The present embodiment provides an anti-inflammatory and anti-acne facial cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 40% horse oil, 5% cetearyl alcohol, 3% PEG-100 stearate, and 5% natural 16 alcohol; the components of phase B include: 10% water shield polysaccharide extract, 8% licorice extract, 8% calendula extract, 8% chamomile extract, 8% knotweed extract, 8% poria extract, 12% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.2% xanthan gum, 4% sodium hyaluronate, and the amount of the gardenia essential oil is 0.3%.
[0062] The anti-inflammatory and anti-acne facial cream of the present embodiment is prepared by the following steps:
[0063] Mix the components in phase A, then heat phase A to 80°C;
[0064] Mix the components of phase B and heat to dissolve, and raise the temperature to 80°C;
[0065] Add phase B to phase A, start homogenization, set the homogenization speed to 450 rpm, and homogenize for 8 minutes. After homogenization, cool to 50°C, add gardenia essential oil and continue homogenizing to obtain the anti-inflammatory and anti-acne cream. Add gardenia essential oil and continue homogenizing at a speed of 250 rpm for 3 minutes, then stir for 5 minutes and defoam.
[0066] Example 4
[0067] The present embodiment provides an anti-inflammatory and anti-acne facial cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 32% horse oil, 2% cetearyl alcohol, 2% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 30% water shield polysaccharide extract, 4% licorice extract, 4% calendula extract, 4% chamomile extract, 4% knotweed extract, 4% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.3% xanthan gum, 4% sodium hyaluronate, and the amount of the gardenia essential oil is 0.3%.
[0068] The anti-inflammatory and anti-acne facial cream of the present embodiment is prepared by the following steps:
[0069] Mix the components in phase A, then heat phase A to 80°C;
[0070] Mix the components of phase B and heat to dissolve, and raise the temperature to 80°C;
[0071] Add phase B to phase A, start homogenization, set the homogenization speed to 450 rpm, and homogenize for 7 minutes. After homogenization, cool to 40°C, add gardenia essential oil and continue homogenizing to obtain the anti-inflammatory and anti-acne cream. Add gardenia essential oil and continue homogenizing at a speed of 250 rpm for 3 minutes, then stir for 5 minutes and defoam.
[0072] Comparative Example 1
[0073] The difference from Example 2 is that the licorice extract is replaced by an equivalent water shield polysaccharide extract, and the chamomile extract is replaced by an equivalent calendula extract, and the preparation method is the same as that of Example 2; this comparative example proposes an anti-inflammatory and anti-acne cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 30% horse oil, 2% cetearyl alcohol, 1.5% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 26% water shield polysaccharide extract, 12% calendula extract, 6% knotweed extract, 6% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil is 0.1%.
[0074] Comparative Example 2
[0075] The difference from Example 2 is that the knotweed extract is replaced by an equivalent water shield polysaccharide extract, and the Poria extract is replaced by an equivalent chamomile extract, and the preparation method is the same as that of Example 2; this comparative example proposes an anti-inflammatory and anti-acne cream, which is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 30% horse oil, 2% cetearyl alcohol, 1.5% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 26% water shield polysaccharide extract, 6% licorice extract, 6% calendula extract, 12% chamomile extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil is 0.1%.
[0076] Related tests
[0077] 1. Appearance of facial cream: The matrix should be uniform, without oil-water separation, and there should be no granular feeling when applied to the skin.
[0078] 2. Stability:
[0079] 1) Centrifugal stability: Take an appropriate amount of cream sample in a centrifuge tube and centrifuge it at 3000r / min, 6000r / min and 10000r / min for 10 min respectively to observe whether there is any separation and stratification of water and oil;
[0080] 2) pH meter to test the pH value: Take 2g of the cream sample, add 20mL of deionized water to dissolve, and ultrasonically vibrate for 15min until it is evenly dispersed. Take out the solution and measure its pH value with a calibrated pH meter;
[0081] 3) Cold resistance test: Store in a refrigerator at -20℃ for 24 hours and then take it out. After returning to room temperature, observe that there should be no oil-water separation or the oil yield should not be greater than 3%;
[0082] 4) Heat resistance test: Place at about 40℃ for 24 hours and then take it out. After returning to room temperature, observe that there should be no oil-water separation or the oil yield should not be greater than 3%.
[0083] 3. Moisture retention: Mainly simulate the skin surface by using a glass plate with medical tape attached. Apply an appropriate amount of sample on the glass plate and place it in a 40°C oven. Weigh its mass every 10 minutes and calculate the water loss after one hour: water loss rate = (m0-m) / m0×100%.
[0084] 4. Anti-ultraviolet property: Take 50 mg of the cream sample in a small beaker, add appropriate amount of deionized water and stir, then transfer to a 50 mL volumetric flask, and ultrasonically vibrate for 25 minutes until the paste is evenly dispersed. Deionized water is used as a reference in the experiment, and the absorption spectrum at a wavelength of 300-400 nm is measured with an ultraviolet spectrophotometer.
[0085] 5. Antioxidant properties:
[0086] 1) DPPH method: The ethanol or methanol solution of DPPH (1,1-Dipheny-2-picrylhaydrazyl) is dark purple and has a strong absorption value at 517nm. After adding the test sample, the color changes due to the scavenging of free radicals. This characteristic is used to detect the antioxidant activity of the sample. At present, the DPPH method has been widely used for the quantitative analysis of free radical scavenging ability.
[0087] Dissolve DPPH radical in anhydrous ethanol to prepare 0.1mmol / L DPPH solution, dilute the sample to 10% sample solution, add 2mL sample solution to a test tube, add 2mL DPPH solution, shake and place in the dark for 30min, measure the absorbance at 517nm, DPPH radical scavenging rate = [1-(A1-A2) / A0] × 100%. A1 refers to the absorbance of the mixture of sample and DPPH solution, A2 refers to the absorbance of the mixture of sample and anhydrous ethanol, and A0 refers to the absorbance of the mixture of DPPH and anhydrous ethanol. Repeat three times for each group and take the average value.
[0088] Table 1. Samples corresponding to A0, A1 and A2
[0089]
[0090] 2) Hydroxyl radical scavenging experiment: The principle is that divalent iron ions react with H2O2 to generate hydroxyl radicals, which react with salicylic acid to form a colorimetric reaction with a maximum absorption peak at 510nm. After the sample solution is added to the reaction system, it reacts with the hydroxyl radicals, resulting in a reduction in the number of free radicals combined with salicylic acid. Therefore, by measuring the absorbance at 510nm, the ability of the sample to scavenge hydroxyl radicals can be calculated.
[0091] Specifically, the salicylic acid method is used: dilute the sample to a 10% sample solution, add 0.5 mL of distilled water and 1 mL each of 6 mmol / L FeSO4 solution, 6 mmol / L H2O2 solution, and 6 mmol / L salicylic acid solution to 0.5 mL of the sample solution, shake well, place in a 37°C constant temperature water bath for 30 minutes, and measure the absorbance at a wavelength of 510 nm (A3). Adjust to zero with distilled water, then replace the 6 mmol / L H2O2 solution with distilled water, measure the absorbance of the sample background tube (A4), and replace the sample solution with distilled water as a blank control group (A5), as shown in Table 2.
[0092] Table 2. Samples corresponding to A3, A4 and A5
[0093]
[0094] The calculation formula is as follows: Hydroxyl radical scavenging rate (%) = [A5-(A3-A4)] × 100% / A5
[0095] 6. Antibacterial properties:
[0096] 1) Preparation of TSA medium (agar solid medium): Weigh 4.0 g of TSA into a 100 mL beaker, preheat the water bath to 50°C, place it in a beaker to allow it to completely dissolve, and then add water to 100 mL.
[0097] Preparation of TSB medium (liquid suspension without agar): Weigh 3.0 g of TSB into a 100 mL beaker, preheat the water bath to 50°C, put it in to completely dissolve it, and then add water to make up to 100 mL.
[0098] 2) Activation of bacteria:
[0099] Place the spare test tubes, culture dishes, coating rods, tweezers, sterile water and prepared culture medium in a 0.1MPa, 121℃ autoclave for sterilization, then move to a clean bench, irradiate under UV light for 15 minutes, ventilate, wait for the culture medium temperature to drop, pour TSB liquid culture medium into the sterilized test tubes, carefully inoculate Escherichia coli and Staphylococcus aureus into the corresponding liquid culture medium (3 tubes of each, 20μL of bacterial solution in each tube), and pay attention to avoid bacterial contamination during the entire operation. After inoculation, place in a shaker at 37℃ for 1 day and observe the turbidity.
[0100] 3) Preparation of solid culture medium:
[0101] Move the sterilized TSA culture medium to the clean bench, irradiate under ultraviolet light for 15 minutes, ventilate, and slowly pour the TSA culture medium into the prepared sterile culture dish before the temperature drops, spread it evenly, and then leave it to cool and solidify, then seal the culture dish with sealing film, mark each bacterial solution and concentration, and place it on the upper layer of the refrigerator for use.
[0102] 4) Determination of antibacterial activity:
[0103] This test uses the filter paper method. The filter paper is cut into certain specifications. After sterilization, the prepared bacterial suspension is taken out and placed in the clean bench. The filter paper is placed in the whitening cream and sterile water respectively and soaked for 30 minutes. Use a pipette to accurately transfer 100 μL of the two bacterial suspensions, add each to the corresponding culture dish, and evenly apply it with a sterilized applicator (prepare two, pay attention to washing and drying when changing the concentration), then take out the soaked filter paper with sterile tweezers, dry it and stick it on the surface of the bacterial plate, 4 pieces per plate. Sterile water is used as a blank control, and this process is completed in the clean bench. Then put the culture dish upside down in a constant temperature incubator at 37°C, take it out after culturing for 24 hours, and measure the diameter of the inhibition zone.
[0104] 7. Whitening performance determination:
[0105] Dilute the sample to a 10% sample solution, take 1 mL of the sample solution, 0.9 mL of a phosphate buffer solution with a pH value of 6.8 and 1 mL of 0.03% tyrosine in a test tube, place in a 37°C constant temperature water bath for 10 minutes, add 0.1 mL of a tyrosinase aqueous solution (1070 U / mL), mix the solution evenly, place in a 37°C constant temperature water bath for 25 minutes, and measure the absorbance value A6 at 475 nm using a spectrophotometer. Replace the tyrosinase aqueous solution with an equal volume of phosphate buffer solution, and measure its absorbance value A7. Replace the sample solution with an equal volume of distilled water, and measure its absorbance value A8. Replace the sample solution with an equal volume of distilled water, and replace the tyrosinase aqueous solution with an equal volume of phosphate buffer solution, and measure its absorbance value A9. Tyrosinase inhibition rate = [(A8-A9)-(A6-A7)] / (A8-A9)×100%.
[0106] 8. Skin irritation test: 24 hours before the experiment, remove the hair on the back of the mouse, and do not damage the epidermis. Take an appropriate amount of sample and apply it on the skin surface. Observe the epidermal reaction 1 hour, 24 hours, and 48 hours after the experiment to determine the intensity of skin irritation. According to the "Safety Technical Specifications for Cosmetics" (2015 edition), score the skin irritation test and refer to the following calculation formula to record the experimental results.
[0107]
[0108] Table 3. Skin irritation response scores
[0109]
[0110]
[0111] Table 4. Skin irritation intensity classification
[0112]
[0113] 9. Sensory evaluation:
[0114] Table 5. Sensory evaluation scores of facial creams
[0115]
[0116]
[0117] Study on the anti-inflammatory and anti-aging effects of facial cream on KM mice:
[0118] 1) Animal materials and reagents: Unmated KM mice (Animal Experiment Center, Huazhong Agricultural University) were raised in an SPF environment with 12 h of light and 12 h of darkness per day, temperature of 25°C, humidity of 45%, and adequate diet; 1-chloro-2,4-dinitrobenzene (DNCB) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., acetone (Batch No. 20220217) was purchased from Sinopharm Chemical Reagent Co., Ltd., and olive oil was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0119] 2) Instruments and equipment: mouse shaver, depilatory cream, high-speed refrigerated centrifuge, grinder, multifunctional microplate reader.
[0120] 3) Establishment of mouse inflammation model: KM mice were randomly divided into a blank group, a model group, a Xiangyi Bencao cream group, a 100% cream group of Example 2, a 75% cream group of Example 2, a 50% cream group of Example 2, a 25% cream group of Example 2, a 100% cream group of Comparative Example 1, and a 100% cream group of Comparative Example 2, with 6 mice in each group. For example, the 50% cream is a concentration obtained by diluting half of the 100% cream with sterilized pure water, and so on. The hair on the back of the mouse was shaved short with a shaver, and then removed with a depilatory cream to expose a skin area of about 3 cm × 3 cm. The blank group was not treated, and the other groups were all modeled with 2% DNCB 100 μL for 4 days, once a day. The degree of skin lesions in the mice could be clearly observed after 4 days. Drug treatment was started on the 5th day for a total of 14 days. Except for the control group, 100 μL of 0.5% DNCB was used to induce once every 4 days. At the end of the experiment, the mouse skin and serum were collected for observation of mouse skin abscesses. After the experiment began, the mouse skin abscesses were observed every day for 7 consecutive days, and the skin of the modeling site of each group of mice was photographed every day.
[0121] 4) Biochemical index detection: Mouse skin tissue was obtained and homogenized in an ice bath at a ratio of tissue mass (g): extract volume (mL) of 1:5-10, centrifuged at 8000 r / min at 4°C for 10 min, and the supernatant was taken. The SOD and GSH contents in the mouse skin tissue were detected according to the relevant instructions of the kit.
[0122] 5) Real-time Quantitative PCR detection of the effect of facial cream on the mRNA content of RELA (NF-κB-p65) and IL-1 in the back lesions of mice:
[0123] ① Extract RNA: Take 40 mg of mouse skin tissue, add 400 μL of cell lysis solution, grind with a freezing grinder, blow repeatedly with a syringe, let it stand for 30 minutes, add neutralizing solution, vortex oscillation for 30 seconds, centrifuge at 12000 rpm at 4°C for 5 minutes, take the supernatant to a 1.5 mL centrifuge tube, add 250 μL of isopropanol and mix evenly, put the preparation tube into a 2 mL centrifuge tube, transfer the above mixed solution to the preparation tube, centrifuge at 6000 rpm at 4°C for 1 minute, discard the filtrate, put the preparation tube back into the 2 mL centrifuge tube, add 500 μL of washing solution to the preparation tube, centrifuge at 4°C Centrifuge at 12000 rpm for 1 min, discard the filtrate, put the preparation tube back into a 2 mL centrifuge tube, add 700 μL of desalting solution to the preparation tube, centrifuge at 12000 rpm at 4°C for 1 min, wash once with 700 μL of desalting solution in the same way, discard the filtrate, put the preparation tube back into the 2 mL centrifuge tube, centrifuge at 12000 rpm at 4°C for 1 min, put the preparation tube into a clean 1.5 mL centrifuge tube, add 70-100 μL of TE water in the center of the preparation tube membrane, let it stand at room temperature for 1 min, centrifuge at 12000 rpm at 4°C for 1 min, and elute RNA.
[0124] ②Measure RNA concentration: Use an ultra-micro UV spectrophotometer to measure the RNA concentration of each sample and keep records.
[0125] ③ Removal of genomic DNA and reverse transcription: Add the corresponding reagents in the reverse transcription kit according to the reagents and usage amounts in Table 6 (operate on ice), gently blow and mix with a pipette, put into the gradient PCR instrument, and adjust the program (42°C 2min) to remove genomic DNA; after the genomic DNA is removed, add the corresponding reagents according to the system in Table 7 (operate on ice), and perform reverse transcription on the gradient PCR instrument (37°C 15min, 83°C 5sec).
[0126] Table 6. Genomic DNA removal reaction system
[0127]
[0128] Table 7. Reverse transcription reaction system
[0129]
[0130] ④Real-time Quantitative PCR reaction: prepare the reaction solution according to Table 8 (operate on ice), apply the three-step PCR amplification program to amplify, obtain the CT value, and finally calculate the 2-ΔΔCT value and draw a graph for comparison.
[0131] Table 8. PCR amplification system
[0132]
[0133] Table 9. PCR primer sequences of target genes
[0134]
[0135] 6)Western blot was used to detect the expression of p-NF-κB p65 and NF-κB p65 proteins in the back skin lesions of mice.
[0136] ① Extract total tissue protein: take about 100 mg of skin tissue for each sample and add 500 μL of tissue lysis buffer (lysis buffer: PMSF: phosphorylation proteinase inhibitor = 100:1:2); fully chop the tissue with a cryogenic grinder, then lyse the tissue suspension on ice for 30 minutes, vortexing once every 10 minutes; after lysis, place it in a 4°C centrifuge at 12,000 rpm for 5 minutes, take the supernatant, mark it, and obtain the protein stock solution, which is stored in a -80°C refrigerator for later use.
[0137] ②BCA protein concentration measurement: Take an appropriate amount of 25mg / mL protein standard solution and dilute it to a final concentration of 0.5mg / mL; set up blank wells, standard wells and sample wells on a 96-well plate, and set up three replicate wells; add 0, 2, 4, 6, 8, 12, 16, and 20μL of the diluted standard to the corresponding wells of the 96-well plate, which is equivalent to the standard concentration of 0, 0.025, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5mg / mL, respectively, and use PBS to make up to 20 μL per well. μL; then, add 20 μL of the diluted sample protein solution to the sample wells of the 96-well plate. Try to avoid contact with the tube wall and the generation of bubbles when adding samples. After the addition is completed, add 200 μL of BCA working solution to each well (mixed by A working solution: B working solution at a volume ratio of 50:1). The order of addition is consistent with the order of protein solution addition; after the addition is completed, place the 96-well plate at room temperature for 2 hours, and use an enzyme reader to measure the optical density (OD value) of each well at a wavelength of 562 nm to calculate the concentration of each sample protein stock solution.
[0138] ③ Protein denaturation: Take an appropriate amount of protein stock solution, add an appropriate proportion of 5× protein loading buffer (5× loading) to dilute it to 1× loading, place it in a 100°C water bath for 8 minutes, and temporarily store it in a -20°C refrigerator after denaturation is completed.
[0139] ④ Prepare glue: prepare glue at 10% concentration.
[0140] ⑤ Electrophoresis: Remove the comb, install the gel plate on the electrophoresis instrument, with the thick plate facing outward and the thin plate facing inward, and fill the space formed by the gel plate and the electrophoresis instrument with 1×Tris-glycine electrophoresis solution. Observe whether there is leakage. If there is no leakage, add the Marker and the denatured sample protein to the loading wells in the order of Marker, Control group, XYBC group, 25% concentration cream group, 50% concentration cream group, 75% concentration cream group, 100% concentration cream group, and Marker. The total amount of protein in each well is controlled to be about 20μg. Install the equipment, plug in the electrode, adjust the voltage to 150V for 20min, and then 200V for 30min.
[0141] ⑥ Transfer: Prepare 1× transfer buffer in advance and pre-cool at 4°C. Prepare 2 flat dishes, transfer equipment, plastic tweezers, marked PVDF membrane, and filter paper before transfer. Take a flat dish, pour a small amount of 1× transfer buffer to soak the filter paper, pour a small amount of ethanol into another flat dish, immerse the PVDF membrane in ethanol to activate it, and then soak it in 1× transfer buffer; cut the gel block where the target protein is located, clamp it in the order of white board (below) → 2 layers of filter paper → PVDF membrane → gel → 2 layers of filter paper → black board (above), and put it into the transfer tank in the order of red to white and black to black, insert the electrodes, adjust the current to 200mA, and transfer for 70min.
[0142] ⑦ Blocking: Prepare 1×TBST in advance, weigh 1g skim milk powder, add 20mL 1×TBST and vortex for 5min to fully dissolve it to prepare 5% milk. After the transfer is completed, take out the transfer clip, take out the PVDF membrane with tweezers and place it in the incubation box, immerse the PVDF membrane completely in milk, and block it for 1h on a shaker at 60 speed.
[0143] ⑧ Incubate the primary antibody: After blocking, pour out the milk, wash the membrane 5 times with 1×TBST at 60 rpm on a horizontal shaker, 5 min each time, and dilute the primary antibody β-actin (1:5000), NF-κBp65 (1:5000), p-NF-κB p65 (1:1000) and goat anti-rabbit secondary antibody (1:8000) with 5% skim milk according to the required proportion for use. Add 5 mL of the primary antibody to each target band, immerse the membrane completely, and incubate at 4°C overnight. The next day, take out the membrane and place it on a room temperature shaker at 60 rpm and wash it 5 times with 1×TBST, 5 min each time, and the primary antibody incubation is complete.
[0144] ⑨ Incubate with secondary antibody: Thaw the secondary antibody that has been diluted in advance and stored in a -20℃ refrigerator, and add 5 mL to the corresponding strips so that the strips are completely immersed. Incubate at room temperature for 40 minutes on a shaker at 60 rpm, then wash 5 times with 1×TBST, 5 minutes each time, and the secondary antibody incubation is complete.
[0145] ⑩ Luminescence: The luminescent solution was prepared in a 1:1 ratio before use, and the chemiluminescence imaging system was used to emit light and save the image.
[0146] The data were expressed as mean ± standard deviation and analyzed using GraphPad Prism statistical software. One-way analysis of variance was used to compare differences among the groups. p < 0.05 indicated a statistically significant difference.
[0147] (II) Test results:
[0148] 1. Appearance and properties: The prepared cream has moderate consistency, is relatively fine, milky white, easy to apply, has no obvious particles when applied on a glass plate, has a uniform matrix, bright color, no peculiar smell, and has the scent of gardenia.
[0149] 2. From the data in Table 10, it can be seen that the facial cream proposed by the present invention has stable performance.
[0150] 3. From the data in Table 11, it can be seen that the water loss rates of cream embodiments 1-4, commercially available herbal cream and distilled water are 7.98%, 7.72%, 8.00%, 8.01%, 8.45% and 19%, respectively. The water loss rates of the cream proposed by the present invention are lower than those of the commercially available herbal cream and distilled water. It can be seen that the moisturizing ability of the cream proposed by the present invention is better than that of the commercially available herbal cream.
[0151] 4. From the data in Table 12, it can be seen that the absorbance values of the cream embodiments 1-4 are significantly greater than the absorbance of the commercially available Herborist brand cream. It can be seen that the ultraviolet absorption capacity of the cream proposed in the invention is better than that of the commercially available Herborist brand cream.
[0152] 5. The results of the antioxidant capacity experiment are shown in Tables 13 and 14. The DPPH free radical inhibition rate and hydroxyl free radical inhibition rate of the cream formula embodiments 1-4 are significantly greater than the inhibition rate of the commercially available Xiangyi Bencao brand cream. It can be seen that the antioxidant capacity of the cream proposed by the present invention is better than the commercially available Xiangyi Bencao cream.
[0153] 6. The results of the antibacterial and whitening experiments are shown in Tables 15 and 16, respectively. Compared with the negative control water and the commercially available Herbal Cream, the cream embodiments 1-4 all showed obvious antibacterial properties. The tyrosinase inhibition rate was also significantly greater than that of the commercially available Herbal Cream. It can be seen that the cream proposed by the present invention has strong antibacterial properties and better whitening ability than the commercially available Herbal Cream.
[0154] 7. The skin irritation test and sensory evaluation are shown in Tables 17 and 18 respectively. The mice skin had no erythema or edema, and the cream proposed by the present invention was safe and non-irritating. The current feedback results show that the evaluation index scores of the cream proposed by the present invention were all between 6 and 8 points, with good sensory evaluation.
[0155] 8. The results of the anti-oxidation determination indexes of mouse skin tissue are shown in Table 19. Compared with the blank group, the SOD and GSH activities of the model group mice were significantly lower than those of the blank group, indicating that the modeling was successful. Compared with the blank group mice, the GSH activities of the Xiangyi Bencao group, 25% concentration cream group, 50% concentration cream group, 75% concentration cream group, and 100% concentration cream group were significantly increased, and the GSH activities of each concentration cream group were greater than that of the Xiangyi Bencao cream group, and the higher the concentration of the cream, the more significant the effect; compared with the blank group mice, the SOD activities of the 75% concentration cream group and the 100% concentration cream group were significantly increased and greater than that of the Xiangyi Bencao cream group. Example 1, Examples 3-4 have antioxidant properties comparable to those of Example 2. The results show that the cream proposed by the present invention can exert its antioxidant effect by enhancing the activities of SOD and GSH in skin tissue.
[0156] 9. The results of the effect of the cream on the expression of IL-1 and NF-κB p65 mRNA in the back lesions of mice are as follows: In the NF-κB classical pathway, when IL-1 binds to the relevant receptor, it will activate IkBa kinase, which can phosphorylate IkBa, and then release NF-κB from the cytoplasmic NF-κB / IkBa complex through ubiquitination, and activate to form p50 / RelA dimer, which rapidly undergoes nuclear translocation, and binds to the eB response element of the target gene through the p50 subunit, thereby activating the expression of target genes such as interleukin 1 to stimulate inflammation. It can inhibit the activity of the NF-κB pathway by inhibiting NF-κB phosphorylation, blocking its nuclear localization and binding to DNA, and inhibiting the expression of target genes (such as IL-1), thereby reducing the occurrence of inflammatory reactions. Figure 1 It can be seen that repeated stimulation of DNCB solution (model group) increased the expression of IL-1 mRNA in the mouse skin lesions and decreased the expression of RELA (NF-κB-p65) mRNA. After intervention with the cream, the following results appeared: 1. The IL-1 mRNA level in the skin lesions of the five treatment groups decreased, and the degree of decrease was more obvious with the increase of the cream concentration. The 100% concentration cream group had the strongest ability to reduce the IL-1 level in the skin lesions (p<0.05). 2. The RELA (NF-κB-p65) mRNA level in the skin lesions of the five treatment groups increased, and the degree of increase was more obvious with the increase of the cream concentration. The 100% concentration cream group had the strongest ability to increase the RELA (NF-κB-p65) level in the skin lesions (p<0.05). The results show that the cream has the ability to inhibit NF-κB phosphorylation and reduce IL-1 inflammatory factors, and the higher the concentration of the cream, the better the inhibitory effect, indicating that the cream has good anti-inflammatory ability.
[0157] 10. The results of the effect of facial cream on the expression of p-NF-κB p65 and NF-κB p65 protein in the back lesions of mice are as follows:
[0158] Western blot results showed that DNCB stimulation increased the protein ratio of p-NFκB p65 / NFκB p65; after the intervention of the cream of the present invention, the ratio decreased, and the decrease was more obvious in the 75% and 100% concentration cream groups (p<0.05) (see Figure 2 ), indicating that the facial cream of Example 2 at 75% and 100% concentrations can better inhibit the activation of NFκB p65 protein.
[0159] In summary, the facial cream developed by the present invention can inhibit the activation of the NF-κB signaling pathway, reduce the expression level of inflammatory factors, and improve the inflammatory condition. It has certain anti-inflammatory, moisturizing, antioxidant, antibacterial and whitening abilities, has little skin irritation, has good sensory evaluation, and has good market development prospects.
[0160] Table 10. Comparative analysis of physical and chemical indicators of facial creams
[0161]
[0162]
[0163] Table 11. Water loss rate of facial cream
[0164]
[0165]
[0166] Table 12. Anti-ultraviolet ability of facial cream
[0167]
[0168]
[0169] Table 13. DPPH free radical inhibition rate
[0170]
[0171]
[0172]
[0173] Table 14. Hydroxyl free radical inhibition rate
[0174]
[0175]
[0176] Table 15. Diameter of inhibition zone (mm)
[0177]
[0178]
[0179] Table 16. In vitro tyrosinase inhibition rate
[0180]
[0181]
[0182] Table 17. Skin irritation intensity table
[0183]
[0184] Table 18. Sensory evaluation score sheet
[0185]
[0186]
[0187] Table 19. Antioxidant index determination results
[0188]
[0189] Compared with the prior art, other technical effects of the present invention include:
[0190] 1) The ingredients are pure natural plant-derived ingredients, do not contain harmful chemical ingredients, and are highly safe;
[0191] 2) The cream system is an oil-in-water microemulsion system. The oil wraps the effective ingredients of Chinese herbal medicine to form tiny droplets that are evenly dispersed in the system. It has good stability and can make the effective substances penetrate the skin better, deeply activate cells, and replenish collagen;
[0192] 3) It has good anti-inflammatory, moisturizing, whitening and other effects, and adds a variety of traditional Chinese medicine active ingredients to work synergistically to improve skin condition;
[0193] 4) Horse oil is added, which can treat atopic dermatitis and dry skin, has an antibacterial effect on Propionibacterium acnes and Staphylococcus aureus, and can produce anti-inflammatory and anti-aging effects;
[0194] 5) The added emulsifier cetearyl alcohol and thickener natural 16 alcohol are natural derived substances with strong emulsifying ability. Adding them to the cream can make the skin texture smooth, fill the skin stratum corneum, and achieve a moisturizing effect;
[0195] 6) The use of ultrasonic-assisted extraction to extract effective substances can accelerate the dissolution and release of the extract, greatly increase the extraction capacity, and effectively solve the problems of long time and low extraction efficiency of traditional extraction methods. At the same time, the process can be implemented at a lower temperature, thereby minimizing thermal damage to the extract, which is in line with the concept of saving resources.
[0196] The specific implementation of the present invention described above does not constitute a limitation on the protection scope of the present invention. Any other corresponding changes and modifications made based on the technical concept of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. An anti-inflammatory and anti-acne cream. It is characterized in that The invention is obtained by mixing phase A, phase B and gardenia essential oil. Calculated by mass percentage, the components of phase A include: 30-40% horse oil, 2-5% cetearyl alcohol, 1.5-3% PEG-100 stearate, and 3-5% natural 16 alcohol; the components of phase B include: 10-30% water shield polysaccharide extract, 4-8% licorice extract, 4-8% calendula extract, 4-8% chamomile extract, 4-8% knotweed extract, 4-8% poria extract, 10-15% peony root bark solution, 1-2% ascorbic acid solution, 2-3% arbutin solution, 0.2-0.3% xanthan gum, and 4%-5% sodium hyaluronate; the amount of the gardenia essential oil is 0.1-0.3%.
2. The anti-inflammatory and anti-acne cream according to claim 1, It is characterized in that The components of phase A include: 30% horse oil, 2% cetearyl alcohol, 1.5% PEG-100 stearate, and 3% natural 16 alcohol; the components of phase B include: 20% water shield polysaccharide extract, 6% licorice extract, 6% calendula extract, 6% chamomile extract, 6% knotweed extract, 6% poria extract, 10% peony root bark solution, 1% ascorbic acid solution, 2% arbutin solution, 0.25% xanthan gum, and 4% sodium hyaluronate; the amount of gardenia essential oil used is 0.2%.
3. The anti-inflammatory and anti-acne cream according to claim 1, It is characterized in that The herbal drug concentration of the Brasenia schrenkiana polysaccharide extract, the Licorice extract or the Poria cocos extract is 0.1-0.15 g / mL, and the Brasenia schrenkiana polysaccharide extract, the Licorice extract or the Poria cocos extract is prepared by the following steps: The water shield powder, licorice powder or poria powder are respectively mixed with water at a material-liquid mass ratio of 1:40-50, ultrasonically extracted at 60-80°C, and then filtered and centrifuged to obtain the product.
4. The anti-inflammatory and anti-acne cream according to claim 1, It is characterized in that The crude drug concentration of the calendula extract or the chamomile extract is 0.1-0.15 g / mL, and the calendula extract or the chamomile extract is prepared by the following steps: Calendula powder or chamomile powder is mixed with ethanol solution at a material-liquid mass ratio of 1:20-25, reacted in a water bath at 55-60° C. for 2-2.5 hours, then activated carbon powder is added for decolorization, and then filtered to obtain the calendula extract or the chamomile extract.
5. The anti-inflammatory and anti-acne cream according to claim 1, It is characterized in that The crude drug concentration of the polygonum cuspidatum extract is 0.1-0.15 g / mL, and the polygonum cuspidatum extract is prepared by the following steps: The knotweed powder and water are mixed, and the mixture is soaked at 35-40°C to obtain a knotweed liquid. Cellulase solution is added to the knotweed liquid, and the mixture is extracted at 45-50°C and filtered. The filtrate is inactivated to obtain a supernatant, the supernatant is centrifuged and activated carbon is added, and then filtered and concentrated to obtain the knotweed extract.
6. The anti-inflammatory and anti-acne cream according to claim 1, It is characterized in that The mass concentration of the ascorbic acid solution or the arbutin solution is 100-110 mg / mL.
7. A method for preparing the anti-inflammatory and anti-acne cream according to any one of claims 1 to 6, It is characterized in that The following steps are involved: Mix the components in phase A, then heat phase A to 75-80°C; Mix the components of phase B and heat to dissolve, and raise the temperature to 75-80°C; Add phase B to phase A, start homogenization, cool to 40-50° C. after homogenization, add gardenia essential oil and continue homogenization to obtain the anti-inflammatory and anti-acne cream.
8. The method for preparing the anti-inflammatory and anti-acne cream according to claim 7, It is characterized in that Add phase B to phase A, start the homogenization at a speed of 450-500 rpm and homogenize for 5-8 minutes.
9. The method for preparing the anti-inflammatory and anti-acne cream according to claim 7, It is characterized in that Add gardenia essential oil and continue homogenizing at a speed of 250-300 rpm for 2-3 min.
10. The method for preparing the anti-inflammatory and anti-acne cream according to claim 7, It is characterized in that The gardenia essential oil is added and continued to be homogenized, and the mixture is further stirred for 3-5 minutes and then degassed.
